NEWS
PRESS RELEASES
14 04, 2021

ROMARK ANNOUNCES INITIAL RESULTS OF PHASE 3 CLINICAL TRIAL OF NT-300 TABLETS FOR THE TREATMENT OF COVID-19

2021-04-26T14:38:59-04:00April 14th, 2021|Categories: COVID-19 Posts, Press Releases|

- NT-300 reduced progression to severe COVID-19 disease by 85% - Romark is working with FDA and plans to seek Emergency Use Authorization in the U.S. TAMPA, Fla. – April 14, 2021 – Romark announced today initial results of a Phase 3 clinical trial of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets, 300 mg)

28 08, 2020

ROMARK ANNOUNCES FDA APPROVAL OF NEW MANUFACTURING FACILITY IN MANATI, PUERTO RICO

2020-08-28T10:51:31-04:00August 28th, 2020|Categories: COVID-19 Posts, Press Releases|

TAMPA, Fla. - August 20, 2020 – Romark, a research-based pharmaceutical company focused on the discovery, development and delivery of innovative new medicines, primarily in the field of infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's manufacturing facility in Manati, Puerto Rico for the production of ALINIA® (nitazoxanide)

11 08, 2020

ROMARK INITIATES NEW PHASE 3 CLINICAL TRIAL OF NT-300 FOR THE TREATMENT OF COVID-19

2020-08-11T10:07:06-04:00August 11th, 2020|Categories: COVID-19 Posts, Press Releases|

NT-300 clinical program now comprises three pivotal trials for COVID-19   TAMPA, Fla. – August 11, 2020 – Romark, a research-based pharmaceutical company focused on the discovery, development and delivery of innovative new medicines, primarily in the field of infectious diseases, announced today the initiation of a Phase 3 clinical trial of its investigational new drug

24 06, 2020

ROMARK INITIATES PHASE 3 CLINICAL TRIALS OF NT-300 FOR COVID-19

2020-06-25T16:45:53-04:00June 24th, 2020|Categories: COVID-19 Posts, Press Releases|

Clinical Development Program for NT-300 Includes Trials Addressing Prevention and Treatment of COVID-19 and Other Viral Respiratory Illnesses   TAMPA, Fla. – April 27, 2020 – Romark announced today it will initiate two clinical trials of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets) for prevention of COVID-19 and other viral respiratory illnesses in high-risk